JP7840267B2 - 筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン－２ - Google Patents

筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン－２

Info

Publication number
JP7840267B2
JP7840267B2 JP2022553666A JP2022553666A JP7840267B2 JP 7840267 B2 JP7840267 B2 JP 7840267B2 JP 2022553666 A JP2022553666 A JP 2022553666A JP 2022553666 A JP2022553666 A JP 2022553666A JP 7840267 B2 JP7840267 B2 JP 7840267B2
Authority
JP
Japan
Prior art keywords
human
treatment
pharmaceutical composition
treg
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022553666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516774A (ja
JP2023516774A5 (https=
Inventor
ギルバート、ベンシモン
ピーター、ナイジェル、リー
ティモシー、トゥリー
チェチーリア、ガルレンダ
マッシモ、ロカティ
ジャニーン、カービー
パメラ、ショー
アンドレア、マラスピナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sheffiled, University of
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Centre Hospitalier Universitaire de Nimes
University of Sussex
Humanitas Mirasole SpA
Original Assignee
Sheffiled, University of
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Centre Hospitalier Universitaire de Nimes
University of Sussex
Humanitas Mirasole SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sheffiled, University of, Assistance Publique Hopitaux de Paris APHP, Sorbonne Universite, Centre Hospitalier Universitaire de Nimes, University of Sussex, Humanitas Mirasole SpA filed Critical Sheffiled, University of
Publication of JP2023516774A publication Critical patent/JP2023516774A/ja
Publication of JP2023516774A5 publication Critical patent/JP2023516774A5/ja
Application granted granted Critical
Publication of JP7840267B2 publication Critical patent/JP7840267B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022553666A 2020-03-06 2021-03-05 筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン－２ Active JP7840267B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305241.0 2020-03-06
EP20305241 2020-03-06
PCT/EP2021/055570 WO2021176044A1 (en) 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis

Publications (3)

Publication Number Publication Date
JP2023516774A JP2023516774A (ja) 2023-04-20
JP2023516774A5 JP2023516774A5 (https=) 2024-02-22
JP7840267B2 true JP7840267B2 (ja) 2026-04-03

Family

ID=71083549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553666A Active JP7840267B2 (ja) 2020-03-06 2021-03-05 筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン－２

Country Status (8)

Country Link
US (2) US20230090069A1 (https=)
EP (2) EP4647123A3 (https=)
JP (1) JP7840267B2 (https=)
AU (1) AU2021230103A1 (https=)
CA (1) CA3166887A1 (https=)
ES (1) ES3041723T3 (https=)
TW (1) TWI894224B (https=)
WO (1) WO2021176044A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4630035A1 (en) 2022-12-05 2025-10-15 Centre Hospitalier Universitaire de Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
DK2683395T3 (en) 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov archive: NCT02059759, [2024/12/3検索]，2016年05月30日，https://clinicaltrials.gov/study /NCT02059759?cond=IL-2ALS&rank=4&tab=history&a=14#version-content-panel
ClinicalTrials.gov archive: NCT03039673, [2024/12/3検索]，2019年10月31日，https://clinicaltrials.gov/study/NCT03039673?cond=IL-2ALS&rank=2&tab=history&a=13#version-content-panel
Neurology，2017年，issue 88 (16_supplement)，pp.1-5

Also Published As

Publication number Publication date
AU2021230103A1 (en) 2022-09-22
EP4114440C0 (en) 2025-06-25
US20230090069A1 (en) 2023-03-23
CA3166887A1 (en) 2021-09-10
EP4114440B1 (en) 2025-06-25
TW202146041A (zh) 2021-12-16
EP4647123A3 (en) 2025-12-24
JP2023516774A (ja) 2023-04-20
US20240335510A1 (en) 2024-10-10
EP4647123A2 (en) 2025-11-12
ES3041723T3 (en) 2025-11-14
WO2021176044A1 (en) 2021-09-10
EP4114440A1 (en) 2023-01-11
TWI894224B (zh) 2025-08-21

Similar Documents

Publication Publication Date Title
Vastert et al. Anakinra in children and adults with Still’s disease
Plosker Interferon-β-1b: a review of its use in multiple sclerosis
Pardeo et al. Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies
JP6416855B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
US20240335510A1 (en) Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
Ll Wilkinson et al. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology
US11236158B2 (en) Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
Mitroulis et al. Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities
CN103732241A (zh) 低剂量il-2用于治疗自身免疫相关病症或炎性病症的应用
Ledić Drvar et al. A modern approach to the treatment of plaque psoriasis
Lu et al. Herbal compound cepharanthine attenuates inflammatory arthritis by blocking macrophage M1 polarization
K Oh et al. Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma
KR20190071785A (ko) 인터페론 감마 관련 적응증의 치료 또는 예방을 위한 방법, 조성물 및 투여 요법
McBride et al. Triggers, timescales, and treatments for cytokine-mediated tissue damage
Distler et al. Emerging therapies for the treatment of systemic sclerosis
WO2022106460A2 (en) Steroid sparing
Svanberg Teglgaard et al. Improved innate immune function in patients with chronic lymphocytic leukemia treated with targeted therapy in clinical trials
Fabris et al. Study on the possible role of the-174G> C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis
Guo et al. Recurrent macrophage activation syndrome in patients with refractory systemic lupus erythematosus treated with emapalumab: a case report
Mansour et al. The opposing effects of two gene defects in STX11 and SLP76 on the disease in a patient with an inborn error of immunity
EP4619005A2 (en) Methods for treating rheumatoid arthritis using a syndecan-1 inhibitor or a syntenin-1 inhibitor
Topping et al. sclerosis, Multiple Sclerosis and Related Disorders
EA042261B1 (ru) Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний
AU2005204338A1 (en) Treatment for multiple sclerosis
Alenius BIOMARKERS AND IMAGING P001

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260324

R150 Certificate of patent or registration of utility model

Ref document number: 7840267

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150